[123I]IBZM SPECT was performed only in patients who tolerated drug washout. unit/years (95% CI 0.1 to 5.3). For grafted patients the 2-12 months post-transplantation [18F]fluorodeoxyglucose positron emission tomography (PET) showed striatal/cortical metabolic increase compared to the presurgical evaluation; 4-12 months post-transplantation PET values were slightly decreased, but remained higher than preoperatively. [123I]iodobenzamide single photon emission CT exhibited an increase in striatal D2-receptor density during postgrafting follow-up. == Conclusions == Grafted patients experienced a milder clinical course with less pronounced motor/cognitive decline and associated brain metabolism improvement. Life-time follow-up may ultimately clarify whether transplantation permanently modifies the natural course of the disease, allowing Delta-Tocopherol longer sojourn time at less severe clinical stage, and improvement of overall survival. Keywords:Huntington’s, Stereotaxic Surgery == Introduction == Human fetal striatal transplantation is being investigated as you possibly can treatment for Huntington’s disease (HD),1with the goal of restoring striatal function impaired by primary degeneration.2Pilot studies have demonstrated the feasibility and safety of the therapy. 38Imaging has shown controversial data on survival and efficacy of the graft,810and long-term pathological studies reported its eventual neuronal degeneration.11Different graft growth patterns have been described.561214Even though alloimmunisation has been reported,1316and its possible role in graft degeneration has been hypothesised,17the host/graft immune response is not well understood. Neoplastic/teratogenic transformation of the graft has never been observed, while the occurrence of overgrowth has seldom been reported.18According to a few long-term follow-up studies, fetal striatal transplantation provided a period of clinical improvement in three out of five patients,9stability in one out of two,10while no significant clinical benefit was found in a group Delta-Tocopherol of five patients compared with 12 non-grafted patients.8We report the results of a follow-up study designed to assess disease progression in 10 consecutive HD transplanted patients and 16 HD not-transplanted patients, and Delta-Tocopherol discuss how fetal striatal transplantation may affect the disease course. == Patients and methods == The present clinical investigation has been conducted according to the Declaration of Helsinki principles. The study begun in 2004 and it was authorised by the Italian National Health Institute, National Transplantation Centre (upon approval by Health Ministry, Consiglio Superiore di Sanit, Sessione XLV, Sezione II, 21 July and 22 September 2005, and acceptance by the National Bioethics Committee). In particular, items to be fulfilled included: (1) distinct separation between the research team and the institution carrying out the pregnancy interruption, (2) lack of benefits for the transplantation and obstetric teams and (3) request of donor’s consent after pregnancy interruption. All patients gave written informed consent prior to being enrolled in the study. All were included Rabbit Polyclonal to PKR in the European HD Network REGISTRY.19 The design is an observational cohort aimed at describing the disease evolution since onset of symptoms and any putative changes after transplantation. The series consisted of 26 HD patients (tables 1and2) who were acquainted with the transplantation programme and adhered to the protocol. Ten patients asked to undergo transplantation and were grafted between 2006 and 2008patients 1, 4, 6, 8 having been partially described.1314All patients were evaluated with the Unified HD Rating Scale (UHDRS)20high functional and cognitive scores denote better performance, low behavioural and motor scores denote better performance. Moreover, grafted patients were evaluated according to Core Assessment Program for Intracerebral Transplantation21and received MRI, [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) and, after a 10-day drug wash-out, [123I]iodobenzamide ([123I]IBZM) single photon emission CT (SPECT). Details of imaging techniques are provided in online-only material. == Table 1. == Demographic and clinical characteristics of 10 Huntington’s disease patients who underwent.